Tracking Therapy Response in Glioblastoma Using 1D Convolutional Neural Networks
Ortega-Martorell, Sandra (Liverpool John Moores University)
Olier, Iván (Liverpool John Moores University)
Hernandez, Orlando (Escuela Colombiana de Ingeniería Julio Garavito)
Restrepo-Galvis, Paula D. (Escuela Colombiana de Ingeniería Julio Garavito)
Bellfield, Ryan A. A. (Liverpool John Moores University)
Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)

Data:	2023
Resum:	Glioblastoma (GB) is a malignant brain tumour with no cure, even after the best treatment. The evaluation of a therapy response is usually based on magnetic resonance imaging (MRI), but it lacks precision in early stages, and doctors must wait several weeks until they are confident information is produced, facing an uncertain time window. Magnetic resonance spectroscopy (MRS/MRSI) can provide additional information about tumours and their environment but is not widely used in clinical settings since the spectroscopy format is not standardised as MRI is, and doctors are not familiarised with outputs/interpretation. This study aims to improve the assessment of the treatment response in GB using MRSI data and machine learning, including state-of-the-art one-dimensional convolutional neural networks. Preclinical (murine) GB data were used for developing models that successfully identified tumour regions regarding their response to treatment (or the lack thereof). These models were accurate and outperformed previous methods, potentially providing new opportunities for GB patient management. Background: Glioblastoma (GB) is a malignant brain tumour that is challenging to treat, often relapsing even after aggressive therapy. Evaluating therapy response relies on magnetic resonance imaging (MRI) following the Response Assessment in Neuro-Oncology (RANO) criteria. However, early assessment is hindered by phenomena such as pseudoprogression and pseudoresponse. Magnetic resonance spectroscopy (MRS/MRSI) provides metabolomics information but is underutilised due to a lack of familiarity and standardisation. Methods: This study explores the potential of spectroscopic imaging (MRSI) in combination with several machine learning approaches, including one-dimensional convolutional neural networks (1D-CNNs), to improve therapy response assessment. Preclinical GB (GL261-bearing mice) were studied for method optimisation and validation. Results: The proposed 1D-CNN models successfully identify different regions of tumours sampled by MRSI, i. e. , normal brain (N), control/unresponsive tumour (T), and tumour responding to treatment (R). Class activation maps using Grad-CAM enabled the study of the key areas relevant to the models, providing model explainability. The generated colour-coded maps showing the N, T and R regions were highly accurate (according to Dice scores) when compared against ground truth and outperformed our previous method. Conclusions: The proposed methodology may provide new and better opportunities for therapy response assessment, potentially providing earlier hints of tumour relapsing stages.
Ajuts:	Agencia Estatal de Investigación PID2020-113058GB-I00 Ministerio de Sanidad y Consumo CB06/01/0010
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Therapy response ; Glioblastoma ; Temozolomide ; Preclinical models ; Magnetic resonance spectroscopy ; Class activation mapping ; Grad-CAM ; Convolutional neural networks ; Deep learning
Publicat a:	Cancers, Vol. 15, Num. 15 (August 2023) , art. 4002, ISSN 2072-6694

DOI: 10.3390/cancers15154002
PMID: 37568818

20 p, 1.7 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats